the PTP1 B-tetrapeptide complex is 0.26 A, and those between the PTP1 B-pTyr complex and the PTP1 B-hexapeptide and PTP1 B-tetrapeptide complexes are 0.38 and 0.40 A, respectively. Equivalent atoms of the hexapeptide and tetrapeptide superimpose within an rms deviation of 0.54 A. The side chain of free pTyr superimposes exactly with the side chain of pTyr within the peptides. The rotomer conformation of free pTyr differs from that of a pTyr residue in a peptide because the Cao-C1 bond is rotated 1200 to avoid close contact of its COOH group with the side chain of Asp48. Excluding residues 179 to 187, the rms deviation of main-chain atoms between the PTP1 B-hexapeptide complex and unliganded PTP1 B is 0.45 A. The structures of unliganded wildtype and C215S PTP1 B are essentially identical (Z. Jia and D. Barford, unpublished data).
The rate-limiting step in cholesterol biosynthesis in mammals is catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a four-electron oxidoreductase that converts HMG-CoA to mevalonate. The crystal structure of HMG-CoA reductase from Pseudomonas mevalonil was determined at 3.0 angstrom resolution by multiple isomorphous replacement. The structure reveals a tightly bound dimer that brings together at the subunit interface the conserved residues implicated in substrate binding and catalysis. These dimers are packed about a threefold crystallographic axis, forming a hexamer with 23 point group symmetry. Difference Fourier studies reveal the binding sites for the substrates HMG-CoA and reduced or oxidized nicotinamide adenine dinucleotide [NAD(H)] and demonstrate that the active sites are at the dimer interfaces. The HMG-CoA is bound by a domain with an unusual fold, consisting of a central a helix surrounded by a triangular set of walls of sheets and cx helices. The NAD(H) is bound by a domain characterized by an antiparallel p structure that defines a class of dinucleotide-binding domains.
The biosynthesis of cholesterol is regulated at the level of the enzyme HMG-CoA reductase, which catalyzes the interconversion of HMG-CoA and mevalonate. This reaction is the first committed step in the pathway of isoprenoid biosynthesis. In mammals, >90% of the bulk carbon flow along this pathway is used in the production of cholesterol. Although cholesterol is an essential C. M. Lawrence tTo whom correspondence should be addressed. component of mammalian cell membranes, its deposition in atherosclerotic plaques restricts blood flow, an important factor in heart disease and death by stroke or heart attack. The abundance of mammalian HMGCoA reductase is normally controlled through the regulation of transcription (1) , translation (2) , and enzyme degradation (3) , whereas the activity of the enzyme is inhibited by phosphorylation (4) . Inhibition of HMG-CoA reductase by drugs such as lovastatin lowers intracellular cholesterol concentrations (5) and increases both low density lipoprotein (LDL) receptor number and absorption of cholesterol circulating as LDL (6) .
The reaction catalyzed by eukaryotic HMG-CoA reductase is a four-electron NADP(H)-dependent oxidoreduction that requires two molecules of NADPH to reduce HMG-CoA to mevalonate and CoA. The reaction is analogous to the two successive reactions of an aldehyde dehydrogenase and an alcohol dehydrogenase, but is accomplished by a single enzyme. Comparatively little is known of the structural requirements for catalysis by HMG-CoA reductase. Direct participation of cysteines in catalysis, suggested by sensitivity to sulfhydryl reagents (7) (8) (9) (10) , was disproved by elimination of cysteines by site-directed mutagenesis ( I1). Glutamate and histidine residues essential for catalysis have, however, been identified (11) (12) (13) . Sequence analysis of >20 HMG-CoA reductases from yeast to mammals indicates a COOH-terminal catalytic domain of -50 kD and a hydrophobic NH2-terminal membrane-attachment domain of variable length (14) . Mammalia HMG-CoA reductase is thought to be a tive as a homodimer with a monomer mo lecular size of 70 to 100 kD (15) .
We have now determined the cryst structure of Pseudomonas mevalonii HMG CoA reductase, a soluble protein of 45-subunits. Although functionally analogo to the catalytic domain of the larger mam malian enzymes, the Pseudomonas enzy lacks an NH2-terminal membrane anch (7, 16) . Pseudomonas HMG-CoA reductas which functions as a catabolic enzyme, induced by mevalonate, which it conver into HMG-CoA with NAD+ as an oxida (7, 9, 17, 18) . Sequence (12, 13 Recombinant P. mevalonii HMG-Co reductase was overexpressed in Escherich coli and purified to homogeneity as prev ously described ( 16) . Crystals were grown the cubic space group I4132 with a = 229.4 A and two monomers per asymmetric unit (19) . The structure solution (Table 1) (19) . Native and derivative data sets were collected to 2.8 A at 40C on a Rigaku 5-kW rotating anode equipped with two San Diego Multiwire Systems area detectors and integrated with software provided by the manufacturer (25) .
For the native data set, the unweighted Rsym on intensity is 5.6% (all data to 2.8 A, 178,990 observations of 25,001 unique reflections). The heavy-atom data sets are of similar quality and exhibit changes in unit-cell parameters of <0.2%. The fluorescein mercuric acetate (FMA) difference Patterson map was interpreted with a graphical method to determine the positions of FMA in the crystal. Heavy-atom positions in subsequent derivatives were identified in difference Fourier maps. Refinement of heavy-atom parameters and calculation of MIR phases to 3.0 A were performed with the program HALSQ (M. G. Rossmann), giving an overall figure of merit of 0.65. All derivatives share one common site located on the noncrystallographic twofold axis; the FMA and KAuCI4 (1 and 2) derivatives share two sites, whereas the two KAuCI4 derivatives have three sites in common. The inclusion of these common sites artificially inflates the MIR figure of merit. Rotation functions and heavy-atom positions each failed to define a unique molecular twofold axis; thus, initial phase improvement through density modification was limited to solvent flattening with the Wang-Leslie procedure implemented in the CCP4 program suite (26) . An initial mask was generated at 5 A with a conservative 30% solvent content, and was increased stepwise to 48% solvent. The solvent flattening was then extended in steps of one reciprocal lattice point from 5.0 to 3.0 A resolution. The MIR, solventflattened map showed 16 well-defined globular densities of 130 A diameter in the unit cell, each centered around a threefold crystallographic axis. At this point, recognizable secondary structure elements defined the position of a molecular twofold symmetry axis. The inability of the heavy-atom positions to define the axis was explained by their asymmetrical location in only one-half of the molecule or on the noncrystallographic twofold axis. The positions of the molecular twofold axes were perpendicular to the crystallographic threefold axes, defining a packing arrangement with 23 symmetry. This arrangement was confirmed in a general self-rotation function with the program GRLF (27) . The position of the molecular twofold axis was then refined in real space and the map was averaged about this axis with programs from the AVGSYS package (28) . An initial polyalanine tracing of the structure was built into the once averaged map with the program FRODO (29) . With a mask generated from the smeared polyalanine coordinates, cycles of combined molecular averaging and solvent flattening were begun at 5.0 A resolution and extended to 3.0 A in steps of a single reciprocal lattice point with a combination of CCP4 and AVGSYS programs. A full model of the HMG-CoA reductase structure was built into the final 3.0 A averaged, solvent-flattened map with the fragment search option of the program 0 (30) . The sequence fit to the map was confirmed with data from selenomethionine-substituted HMG-CoA reductase (Fig.  1) . The model was improved in cycles of crystallographic refinement with TNT (20) domain. An antiparallel pair of helices (cIA, otB) folds on the exterior of the molecule, followed by an extended loop carrying helix aoC. A long P strand (PA) runs from this loop back to the compact portion of the domain, twisting through 1800 as it crosses the molecule and enters the triangular structure as one of the Pi strands of the o-P wall. The loop between helix otC and 1A in this portion of the structure contains one of the highly conserved sequences of HMG-CoA reductase, EX3GX4P (Table 2) . Although P. mevalonii HMG-CoA reductase uses NAD(H) as a cofactor, it lacks any structure comparable to the classic dinucleotide-binding fold, a six-stranded parallel P sheet with right-handed crossover helices connecting the NH2-and COOHtermini of the sheet strands (22) . The small domain of HMG-CoA reductase defines another class of dinucleotide-binding fold composed of a four-stranded antiparallel P sheet with two crossover helices that lie across one side of the sheet (Fig. 2C) . The first turns of the second crossover helix (aoG) and the preceding loop contain the sequence DAMGXN, another signature sequence for HMG-CoA reductase ( Table 2) .
The packing of the subunits in the crystal reveals a dimer with an extensive intersubunit interface formed by the two monomers in the asymmetric unit (Fig. 3) . A solvent-inaccessible surface area of 4800 A2 per monomer, 28% of the total monomer surface, is buried at the dimer interface. The center of the dimeric structure contains a familiar motif, an antiparallel four-helix bundle. Each monomer contributes two helices (aIl and otj), which cross the corresponding pair at a standard helix interaction angle. In contrast to a typical hydrophobic core, the core of this motif is rich in salt bridges between acidic and basic residues. The intersubunit contacts between the large and small domains form another important interaction in the dimer. The 1 strands of the small domain, which in the monomer extend like the fingers of an open hand, wrap around helix otH in the large domain of the twofold-related monomer.
The NH2-termini of the two subunits, which appear loosely folded in the monomer, form the most complex of the intersubunit interactions (Fig. 3) . The NH2-terminal arm of the large domain reaches toward the large domain of the symmetryrelated monomer, placing the EX3GX4P loop of one monomer adjacent to the catalytic E83 loop ( The monomer interactions of the HMGCoA reductase subunits described above result in a T-shaped dimer (Fig. 3) (Fig. 3) . HMG-CoA is bound predominantly by the large domain of one monomer and NAD(H) by the small domain of the symmetry-related monomer (Fig. 4) . These binding sites bring the two substrates together at the dimer interface, such that the thioester of HMG-CoA and C-4 of the 4 . The active site of P. mevalonli HMG-CoA reductase, viewed in stereo, looking directly into one of the dimer interface active site cavities. This view corresponds to a 900 rotation about the twofold axis of the view shown in Fig. 3 (Table 2) are located in or around the active site cavity. Two conserved NH2-terminal regions, one from each monomer, contribute to the formation of one rim of the active site (Fig. 4) . The PB-aD loop (Fig. 4, blue monomer) lies along one edge of the cavity with the side chain of its Glu83 residue pointing straight down into the active site. This loop is constrained by hydrogen bonds between the side chain of Glu52 of the EX3GX4P loop (red monomer) and main chain amides of the E83 loop (blue monomer). An intersubunit salt bridge between Glu82 and Arg285 also constrains the configuration of the active site E83 loop.
A third conserved region near the active site is the DAMGXN sequence, which is located in the small domain (Fig.  4, red monomer) . The loop and NH2-terminal portion of the helix that constitute this conserved region point down into the active site from the rim of the cavity opposite to the E83 loop. The GX2G2XT motif present in the loop and first turn of helix aK in the large domain is also found along the rim of the active site, where it lies adjacent to the DAMGXN motif of the small domain (Fig. 4, blue monomer) . A fifth conserved region (Table 2) , located immediately beyond the end of the defined structure, contains His381, a residue that is important in catalysis (12) . This region begins at the end of the long central helix (aoM) (Fig. 4, blue monomer) immediately adjacent to the active site. Additional conserved residues located in the active site include Lys267, Asn271, and Asp283 HMG-CoA is bound by the large domain (Fig. 4, blue Difference Fourier studies have revealed the binding sites in the binary enzyme-reductase. The rF-cxG loop runs under the adenine ring and then into helix c-G, whereas helix cxF runs over the adenine to sandwich the ring between the DAM residues of the DAMGXN motif and helix cxF. The 2'-and 3'-OH groups of the adenine ribose are hydrogen-bonded by Asp'46 and Thr189, respectively, whereas the NH2-terminus of helix oaG, GXN of the DAMGXN motif, interacts with the diphosphate moiety of the NAD(H) through the unsaturated amide nitrogens of the helix and the asparagine side chain. Although this subunit has an unusual type of dinucleotide-binding fold, the interactions of the diphosphate of NAD(H) with the NH2-terminus of helix oaG are similar to those in the classic dinucleotide-binding fold. The large domain also participates in binding the NAD(H) cofactor. The results of the two difference Fourier studies show that when either HMGCoA or NAD(H) is bound to the enzyme in the absence of the other, the active site is exposed to the solvent. Typically, hydride ion transfer occurs in an active site that excludes solvent. A solvent-exposed active site also seems unlikely because release of the putative aldehyde intermediate formed between the first and second steps in the reaction has not been detected. In addition, the COOH-terminal 50 residues of the P. mevalonii HMG-CoA reductase molecule, which are disordered in the structure, contain a highly conserved histidine residue, His381, that is essential for catalysis (12, 13) . This residue is only five amino acids beyond the end of the ordered density at the COOHterminus of cxM, the central helix of the large domain. Given these considerations, we propose that the COOH-terminal 50 residues form a third domain, a movable flap that closes over the active site when all substrates are in place. This enclosure would both position the catalytic residue His381 in the active site and isolate the reaction from the solvent.
Structure-based parallels suggest an explanation for a control mechanism for this enzyme in mammals. The activity of HMGCoA reductase in higher eukaryotes is controlled by the phosphorylation of a single serine residue, which in the mammalian enzyme is located six residues beyond the catalytic histidine (4, 23) . From sequence comparisons, this serine residue would also be located on the proposed flexible portion 1762 of the structure, which, although containing fewer residues than in the P. mevalonii enzyme, could also close over the active site on substrate binding. When phosphorylated, the corresponding serine of hamster HMG-CoA reductase appears to interact with the catalytic histidine (24) . This interaction could interfere with closure of the COOH-terminal flexible domain, and thereby control enzyme activity.
Although previous studies of the multimeric state of P. mevalonii HMG-CoA reductase suggested the enzyme was a homotetramer (17) 
